A.I. featured large again last week, mainly because it was the key talking point as five of the Mag 7 companies released earnings with mixed results. The FOMC decision also went as expected, although Mr Powell threw some caution into the wind. Global stock markets took it in stride, but the US Treasury market was less happy as yields rose across the curve. Gold was weaker again, and the US Dollar strengthened.

I am not expert in artificial intelligence, although I do have a basic grasp of its expected benefits balanced by the possible social implications. However, this article focuses on A.I. from an investor's perspective, since the stocks of companies that can attach themselves even loosely to the A.I. narrative have taken off like a rocket.

Bond yields ticked up after an in-line Nov CPI report, reminding investors the inflation battle is not over. Stocks were weaker.,

This is the 3rd and final article focused on anti-obesity drugs. It looks at valuations of shares of the two giants in this biz, LLY & NVO.

Tech companies drove the 7% return of the S&P 500 in the 1Q23. Without the "magnificent seven", the index would have been flattish.

The consensus view is that stocks will rise modestly in 2023. History has proven one thing – analysts will be wrong!

Markets were up on bad economic news, and then faltered on good economic news. The narrative of a Fed pivot won't go away.

This is a monumental week for earnings, with 167 S&P 500 companies – including all five FAMAG big tech companies – reporting results.

Given the poor performance of equities so far this year, I wanted to take a quick high level look at valuations of a number of stocks...